Exploiting the Host-HIV Interface To Identify Biomarkers Predicting Time to Viral Rebound after Treatment Interruption

利用宿主-HIV 界面识别生物标志物，预测治疗中断后病毒反弹的时间

• 批准号: 10223991
• 负责人: Nadia R Roan
• 金额: $ 168.71万
• 依托单位: J. DAVID GLADSTONE INSTITUTES
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-08 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10223991
• 关键词: AIDS clinical trial group; Aftercare; Anti-Retroviral Agents; Antibodies; Antibody Avidity; Antibody titer measurement; Antiviral Agents; Avidity; Berlin; Biochemical Pathway; Bioinformatics; Biological; Biological Assay; Biological Markers; Biometry; Biostatistics Core; Biotechnology; Blood Cells; Boston; CD4 Positive T Lymphocytes; Cells; Cerebrospinal Fluid; Clinic; Clinical; Clinical effectiveness; Complex; Computer software; Consent; Coupled; DNA; DNA Sequence; Dangerousness; Data Analyses; Data Set; Development; Disease remission; Exhibits; Gene Expression; Genes; Gold; HIV; HIV Antibodies; Immune; Immunize; Individual; Inflammation; International; Interruption; Laboratories; Lymphoid Tissue; Measurement; Mediating; Meta-Analysis; MicroRNAs; Molecular; NIH Office of AIDS Research; Nature; Participant; Patient risk; Patients; Phenotype; Plasma; Population; Proviruses; RNA; Recrudescences; Research; Rest; Sampling; Surrogate Endpoint; T-Lymphocyte; Technology; Testing; Therapeutic; Time; Viral; Viral Load result; Virus; Work; acute infection; circulating microRNA; cost; curative treatments; cytokine; deep sequencing; digital; drug development; exhaustion; exosome; experience; extracellular vesicles; falls; high dimensionality; inflammatory marker; innovation; latent HIV reservoir; miRNA expression profiling; microRNA biomarkers; multidimensional data; next generation; novel; predictive marker; programmed cell death protein 1; programs; specific biomarkers; therapeutic candidate; viral DNA; viral rebound; volunteer

Project Summary/Abstract The development and testing of potential HIV cure therapeutics would be greatly expedited by a robust set of biomarkers predicting their clinical effectiveness. Biomarkers that can serve as surrogate endpoints remain unidentified. Such biomarkers will: 1) accelerate progress in the HIV cure arena much like plasma viral load testing propelled antiviral drug development; 2) afford patients participating in analytical treatment interruption (ATI) trials a higher degree of clinical protection by both reducing the number of trials; 3) provide biological clues into the molecular and biochemical pathways that control the latent reservoir; and 4) serve as a magnet for attracting Biotech and Pharma to more vigorously engage in HIV cure research. The BioMark program project team (Warner Greene, Gilad Doitsh, Garry Nolan, Katie Pollard, Satish Pillai, Nadia Roan, and Robert Siliciano) will search for strong biomarkers that accurately predict time to rebound following treatment interruption. Such biomarkers would be of great value for the cure field as they would allow clinicians to predict the period of time a patient can remain off ART without viral recrudescence. Blood cells and plasma from 125 HIV-infected volunteers participating in four different ATI trials obtained before ATI and at the time of viral rebound will be analyzed. These patients include 30 individuals treated during acute infection who are expected to exhibit slower rebound times. To identify both virus- and host-derived biomarkers, the team will 1) deploy an exciting “first in class” digital droplet PCR assay that selectively detects and quantitates intact proviral DNAs (IPDA) in the reservoir––because it is this key small fraction of the total provirus population that contains the infectious proviruses mediating rebound, a low number of intact proviruses might emerge as a strong biomarker predicting a longer time to viral rebound; 2) utilize next-generation ultra-deep sequencing to profile cellular RNAs and miRNAs in CD4 T and other immune cells and in parallel to sequence DNA, RNA and miRNA circulating free in plasma (and in cerebrospinal fluid in a limited subset of subjects) or bound as cargoes in extracellular vesicles to identify predictors of time of viral rebound; 3) use 7 validated CyTOF panels comprising over >200 parameters to phenotypically study CD4 T cells and other immune cells under both resting and stimulated conditions to identify single-cell signatures of time to viral rebound; 4) assess changes in the titer and avidity of circulating anti-HIV antibodies or markers of lymphoid tissue inflammation (including products of pyroptosis) as indicators of the size of the expressed reservoir, which can serve as predictors of time to viral rebound. These studies will generate large bodies of high-dimensional data that will be compiled, curated, and analyzed in BioMark's Bioinformatics and Biostatistics Core. Several biostatistical approaches will be employed to identify these biomarkers and to perform the larger meta analysis (see Core description). In summary, BioMark proposes an innovative and comprehensive approach to fill a major gap in HIV cure research produced by a lack of key biomarkers predicting time to viral rebound after treatment interruption.

项目总结/文摘

项目成果

Immune responses to HIV and SIV in mucosal tissues: 'location, location, location'.

• DOI: 10.1097/coh.0b013e328335c178
• 发表时间: 2010-03
• 期刊: Current opinion in HIV and AIDS
• 影响因子: 4.1
• 作者: Shacklett BL

Phenotype and functionality of CD4+ and CD8+ T cells in the upper reproductive tract of healthy premenopausal women.

健康绝经前女性上生殖道 CD4 和 CD8 T 细胞的表型和功能。

• DOI: 10.1111/aji.12182
• 发表时间: 2014
• 期刊: American journal of reproductive immunology (New York, N.Y. : 1989)
• 作者: Shanmugasundaram,Uma;Critchfield,JWilliam;Pannell,Jane;Perry,Jean;Giudice,LindaC;Smith-McCune,Karen;Greenblatt,RuthM;Shacklett,BarbaraL
• 通讯作者: Shacklett,BarbaraL